[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615837":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":11,"centralContacts":32,"locations":38,"responsibleParty":57,"collaborators":11,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":11,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":11,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",[8,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group A: HRS-9563 or Placebo Injection; low dose","EXPERIMENTAL",null,[13,14],"Drug: HRS-9563 Injection","Drug: sodium chloride injection",{"label":16,"type":10,"description":11,"interventionNames":17},"Treatment group B: HRS-9563 or Placebo Injection; Intermediate dose",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Treatment group C: HRS-9563 or Placebo Injection; Medium to high dose",[13,14],{"label":22,"type":10,"description":11,"interventionNames":23},"Treatment group D: HRS-9563 or Placebo Injection; high dose",[13,14],[25,29],{"type":26,"name":27,"description":27,"armGroupLabels":28,"otherNames":11},"DRUG","HRS-9563 Injection",[9,16,19,22],{"type":26,"name":30,"description":30,"armGroupLabels":31,"otherNames":11},"sodium chloride injection",[9,16,19,22],[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"Yuhan Guo","CONTACT","+0518-81220121","yuhan.guo.yg21@hengrui.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Beijing Anzhen Hospital, Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100029","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54],{"name":55,"role":56,"phone":11,"phoneExt":11,"email":11},"Jun Cai","PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100615837","phase-2-phase-ii-clinical-study-of-hrs-9563-in-patients-with-mild-to-moderate-hypertension-100615837",false,"NCT07297797","Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-9563 in Patients With Mild to Moderate Hypertension","Inclusion Criteria:\n\n1. The subject voluntarily signs the informed consent form.\n2. Male or female, aged ≥ 18 years and ≤ 75 years;\n3. Patients with mild to moderate hypertension;\n4. At the Screening and Baseline periods, the mean sitting office systolic blood pressure is \\> 130 mmHg, and the 24-hour mean systolic blood pressure assessed by ABPM at Screening is ≥ 130 mmHg and \\\u003C 160 mmHg.\n\nExclusion Criteria:\n\n1. Secondary hypertension;\n2. Orthostatic hypotension;\n3. Type 1 diabetes or poorly controlled type 2 diabetes;\n4. Occurrence of any cardiovascular or cerebrovascular event within 6 months prior to screening;\n5. Presence of uncontrolled severe arrhythmia within 6 months prior to screening;\n6. Suspected allergy to the investigational drug or any of its components;\n7. Other diseases requiring Renin-Angiotensin-Aldosterone System (RAAS) inhibitor therapy, besides hypertension;\n8. Any blood biochemical indicator during screening or baseline did not meet the standards in the exclusion criteria;\n9. Use of any medication affecting blood pressure within 4 weeks prior to screening, or planned use during the study period;","ALL","18 Years","75 Years",{"count":70,"type":71},234,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.",[77],"Mild to Moderate Hypertension","2026-01-23",{"date":80,"type":81},"2026-01-26","ACTUAL",{"date":83,"type":81},"2026-01-14",{"date":85,"type":71},"2027-10",{"name":5,"class":6},1]